Screener
Kyverna Therapeutics, Inc. KYTX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Other accrued expenses and current liabilities | 9,222 | 13,472 |
| Operating lease liabilities, short-term portion | 1,764 | 3,662 |
| Finance lease liabilities, short-term portion | 221 | 307 |
| Total current liabilities | 29,674 | 36,487 |
| Operating lease liabilities, net of short-term portion | 6,958 | 320 |
| Term loan | 24,812 | 24,743 |
| Total liabilities | 61,444 | 61,550 |
| Commitments and contingencies (Note 7) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s total current liabilities?
- Kyverna Therapeutics, Inc. (KYTX) reported total current liabilities of $29.67M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s total current liabilities changed year-over-year?
- Kyverna Therapeutics, Inc.'s total current liabilities decreased by 10.9% year-over-year, from $33.29M to $29.67M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s total current liabilities?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s total current liabilities has grown at a 35.5% compound annual growth rate (CAGR), from $19.86M to $36.49M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Kyverna Therapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude